Navigation Links
Mederi Therapeutics Announces Receipt of FDA 510(k) Clearance for the MDRF1 Radiofrequency Generator
Date:1/31/2011

GREENWICH, Conn., Jan. 31, 2011 /PRNewswire/ -- Mederi Therapeutics Inc. announced today that it has received FDA 510(k) clearance for its new MDRF1 Generator.

The Mederi RF Generator powers the Stretta® System for treatment of Gastroesophageal Reflux Disease (GERD) as well as the Secca® System for Bowel Incontinence or Bowel Control Disorder (BCD).

"Today's FDA clearance of the MDRF1 is the culmination of significant investment and design efforts by Mederi. The goal of the MDRF1 project was to produce a system of the highest quality and reliability to treat these two serious and debilitating conditions," stated Will Rutan, Mederi's CEO. "Mederi's new RF generator dramatically reduces the user's capital spending requirements by combining two power generators into one. The MDRF1 is a smaller, lighter and highly portable radiofrequency generator with a more intuitive user interface than its predecessors," continued Rutan.  "The MDRF1 combines the functionality of these earlier models into one system that powers both the Stretta and Secca devices."

The availability of these products represents a significant advancement in minimally invasive options for the millions of people who suffer from GERD or BCD. The treatments involve delivery of radiofrequency energy to the sphincter muscles at either end of the digestive system. Both Secca and Stretta bridge the gap between conservative or pharmacologic therapy and invasive surgery – giving doctors and patients an effective and less complicated alternative.

This FDA 510(k) clearance, as well as our recently awarded CE Mark, and ISO 13485 certification, demonstrate Mederi's steadfast commitment to innovation, safety and quality.

Additional information is available at www.mederitherapeutics.com.

ABOUT MEDERI

Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system. All Mederi therapies are outpatient, minimally invasive, and promote rapid recovery. Mederi Therapeutics is located in Greenwich, Connecticut.

Contact: Sheila Doyle, Manager of Communications and Marketing

203 930 9980


'/>"/>
SOURCE Mederi Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
2. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. PTC Therapeutics President and CEO Elected AAAS Fellow
5. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
6. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
7. Echo Therapeutics to Present at the OneMedForum 2011 Conference
8. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
9. Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
10. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
11. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):